Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Medicines licensing

FDA approves brexpiprazole for schizophrenia and depression

The US Food and Drug Administration (FDA) has approved brexpiprazole (Otsuka Pharmaceutical’s Rexulti) for the treatment of adults with schizophrenia. In the image, Building 66 of the FDA

Source: Wikimedia Commons

The US Food and Drug Administration has approved brexpiprazole for use in schizophrenia and depression but warns that it should not be used to manage behavioural problems in older people with dementia-related psychosis

The US Food and Drug Administration (FDA) has approved brexpiprazole (Otsuka Pharmaceutical’s Rexulti) for the treatment of adults with schizophrenia. The antipsychotic is also approved as an add-on treatment for adults with major depressive disorder (MDD) who are already receiving antidepressant therapy.

Brexpiprazole was discovered by Tokyo-based Otsuka and co-developed with the Danish pharmaceutical company Lundbeck. The companies expect the drug to become available to patients in the United States in early August 2015.

The mechanism of action of brexpiprazole is unknown. However, Otsuka and Lundbeck say its efficacy may be mediated through partial agonist activity at serotonin 5-HT1A and dopamine D2 receptors, and antagonist activity at serotonin 5-HT2A receptors.

The FDA based its decision to approve brexpiprazole for use in schizophrenia on data from two six-week clinical trials, involving 1,310 participants. Brexpiprazole reduced the occurrence of symptoms associated with schizophrenia compared with placebo. The drug was also evaluated in combination with an antidepressant in two six-week trials involving 1,046 participants for whom an antidepressant alone did not adequately treat their symptoms. Patients taking brexpiprazole reported fewer symptoms of depression than those taking placebo.

The most common side effects reported by participants taking brexpiprazole in clinical trials included weight gain and restlessness.

Announcing its decision to approve brexpiprazole, the FDA highlighted that the drug carries a warning about an increased risk of death associated with off-label use to treat behavioural problems in older people with dementia-related psychosis. “No drug in this class is approved to treat patients with dementia-related psychosis,” the FDA states. 

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20068985

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

RPS publications

Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.

Visit rpharms.com

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • The US Food and Drug Administration (FDA) has approved brexpiprazole (Otsuka Pharmaceutical’s Rexulti) for the treatment of adults with schizophrenia. In the image, Building 66 of the FDA

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.